CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Five-Year Follow-Up After Sirolimus-Eluting Stent ImplantationResults of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial
Giora Weisz, MD*,*,
Martin B. Leon, MD*,
David R. Holmes, Jr, MD ,
Dean J. Kereiakes, MD ,
Jeffrey J. Popma, MD ,
Paul S. Teirstein, MD||,
Sidney A. Cohen, MD, PhD¶,#,
Hong Wang, MD, MPH#,
Donald E. Cutlip, MD** and
Jeffrey W. Moses, MD*
* Center for Interventional Vascular Therapy, New York-Presbyterian Hospital, Columbia University, and Cardiovascular Research Foundation, New York, New York
Saint Mary's Hospital, Rochester, Minnesota
Ohio Heart Health Center, Cincinnati, Ohio
St. Elizabeth's Medical Center, Boston, Massachusetts
|| Scripps Clinic and Research Institute, La Jolla, California
¶ University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
# Cordis (Johnson & Johnson), Warren, New Jersey
** Beth Israel Deaconess Medical Center and Harvard Clinical Research Institute, Boston, Massachusetts
Manuscript received January 6, 2008;
revised manuscript received January 7, 2009,
accepted January 12, 2009.
* Reprint requests and correspondence: Dr. Giora Weisz, Center for Interventional Vascular Therapy (CIVT), Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 5th Floor, New York, New York 10032 (Email: gweisz{at}crf.org).
Objectives: The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial.
Background: The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS).
Methods: Patients (n = 1,058) with de novo native coronary artery lesions were randomized to either SES (n = 533) or control BMS (n = 525) and were followed for 5 years.
Results: Between 1 and 5 years, additional clinical events were similarly distributed among the sirolimus and control groups. At 5 years, in sirolimus versus control patients, target lesion revascularization was 9.4% versus 24.2% (p < 0.001) and major adverse cardiovascular events and target vessel failure rates were 20.3% versus 33.5% and 22.5% versus 33.5%, respectively (p < 0.0001 for both). There were no significant differences in death, myocardial infarction, and nontarget lesion revascularization. No significant differences were observed in the cumulative incidence of stent thrombosis for sirolimus versus control patients with either protocol-derived (1.0% vs. 0.8%) or Academic Research Consortium definitions (3.9% vs. 4.2%).
Conclusions: In patients with noncomplex coronary artery disease, clinical outcomes 5 years after implantation of SES continue to demonstrate significant reduction in the need for repeat revascularization, with similar safety (death and myocardial infarction) compared with BMS, without evidence for either disproportionate late restenosis or late stent thrombosis.
Key Words: coronary disease • diabetes mellitus • restenosis • stents • thrombosis
|
Abbreviations and Acronyms
| | ARC = Academic Research Consortium | | BMS = bare-metal stent(s) | | MACE = major adverse cardiac event(s) | | MI = myocardial infarction | | OR = odds ratio | | SES = sirolimus-eluting stent(s) | | TLR = target lesion revascularization | | TVF = target vessel failure | | TVR = target vessel revascularization |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A28.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
W. D. Paulson, N. Kipshidze, K. Kipiani, N. Beridze, M. V. DeVita, S. Shenoy, and S. S. Iyer
Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R)
Nephrol. Dial. Transplant.,
January 11, 2012;
(2012)
gfr667v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Park, I.-H. Chae, D.-S. Lim, K.-R. Han, H.-M. Yang, H.-Y. Lee, H.-J. Kang, B.-K. Koo, T. Ahn, J.-H. Yoon, et al.
Everolimus-Eluting Versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) Randomized Trial.
J. Am. Coll. Cardiol.,
October 25, 2011;
58(18):
1844 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Collet, J. R. Costa, A. Abizaid, D. Chamie, R. Staico, R. Costa, D. Siquera, J. Obregon, F. Feres, A. Sousa, et al.
Assessing the Temporal Course of Neointimal Hyperplasia Formation After Different Generations of Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1067 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane and G. W. Stone
How to Minimize Stent Thrombosis
Circulation,
September 13, 2011;
124(11):
1283 - 1287.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Venkitachalam, Y. Lei, J. M. Stolker, E. M. Mahoney, A. P. Amin, J. B. Lindsey, K. F. Kennedy, M. J. Pencina, J. J. Lopez, N. S. Kleiman, et al.
Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use: Insights From Temporal Analysis of the Multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry
Circulation,
August 30, 2011;
124(9):
1028 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Umeda, T. Kawai, N. Misumida, T. Ota, K. Hayashi, M. Iwase, H. Izawa, S. Sugino, T. Shimizu, Y. Takeichi, et al.
Impact of Sirolimus-Eluting Stent Fracture on 4-Year Clinical Outcomes
Circ Cardiovasc Interv,
August 1, 2011;
4(4):
349 - 354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Raber, L. Wohlwend, M. Wigger, M. Togni, S. Wandel, P. Wenaweser, S. Cook, A. Moschovitis, R. Vogel, B. Kalesan, et al.
Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial
Circulation,
June 21, 2011;
123(24):
2819 - 2828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip
Five-Year Outcomes of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Routine Clinical Practice: Are They Equally Good (or Bad)?
Circulation,
June 21, 2011;
123(24):
2779 - 2781.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, G. Nakazawa, M. W. Krucoff, M. Vorpahl, R. Mehran, A. V. Finn, P. Vranckx, C. Kimmelstiel, C. Berger, J. L. Petersen, et al.
Autopsy Validation Study of the Academic Research Consortium Stent Thrombosis Definition
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
554 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Simsek, M. Magro, E. Boersma, Y. Onuma, S. T. Nauta, M. P. Gaspersz, W. J. van der Giessen, R. T. van Domburg, P. W. Serruys, and on behalf of the Interventional Cardiologists of t
The Unrestricted Use of Sirolimus- and Paclitaxel-Eluting Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) Registries
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yamaji, T. Kimura, T. Morimoto, Y. Nakagawa, K. Inoue, Y. Soga, T. Arita, S. Shirai, K. Ando, K. Kondo, et al.
Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
468 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Teirstein
Drug-Eluting Stent Restenosis: An Uncommon Yet Pervasive Problem
Circulation,
July 6, 2010;
122(1):
5 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis
Percutaneous Left Main Invention: An Evolving Perspective
J. Am. Coll. Cardiol. Intv.,
June 1, 2010;
3(6):
642 - 647.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
May 18, 2010;
55(20):
2272 - 2286.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W Serruys
Drug-eluting stents: a reappraisal
Heart,
April 1, 2010;
96(7):
489 - 493.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Serruys, Y. Onuma, S. Garg, P. Vranckx, B. De Bruyne, M.-C. Morice, A. Colombo, C. Macaya, G. Richardt, J. Fajadet, et al.
5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions
J. Am. Coll. Cardiol.,
March 16, 2010;
55(11):
1093 - 1101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis, G. W. Stone, D. A. Cox, J. Hermiller, C. O'Shaughnessy, T. Mann, M. Turco, R. Caputo, P. J. Bergin, T. S. Bowman, et al.
Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents: 5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1248 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Kugelmass
The quest for a 'better mousetrap'
Eur. Heart J.,
October 2, 2009;
30(20):
2431 - 2432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Drachman
Drug-Eluting Stents in Animals and Patients: Where Do We Stand Today?
Circulation,
July 14, 2009;
120(2):
101 - 103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Long-Term Follow-Up After Sirolimus-Eluting Stent Implantation
Journal Watch Cardiology,
June 10, 2009;
2009(610):
5 - 5.
[Full Text]
|
|
|
|
